Fig. 3From: 18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse gliomaBox plots of the radiomics signature. Box plots of the radiomics signature in the primary (a) and validation cohorts (b). The signature displayed a higher value for the patients with MGMT-methylated tumors in both cohortsBack to article page